argenx Completes Acquisition of Forte Biosciences, Inc.
argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.
Read the full story at GlobeNewswire Inc. ↗IntelliStock summarizes and links to the original publisher. Data delayed 15 minutes.